Maternal and umbilical homocysteine in preeclampsia

Abstract

**Background and purpose:** Were to assess the association between homocysteine levels and development of preeclampsia, to determine homocysteine levels in fetal circulation, to differentiate homocysteine levels in mild and severe preeclampsia and to compare homocysteine levels in pregnant women with preeclampsia with homocysteine levels measured in the same group of women six months after delivery.

**Material and methods:** The study included 55 pregnant women with mild or severe preeclampsia (hypertension with proteinuria), while control group of 50 healthy pregnant women. Maternal and umbilical blood homocysteine levels were determined by the fluorescence polarization immunoassay. Shapiro-Wilks, Mann-Whitney and Wilcoxon statistical tests performed for statistical analysis.

**Results:** In women with preeclampsia, the mean homocysteine level was by 0.744 µmol/L higher than in control women; with mild preeclampsia, the level was by 2.752 µmol/L lower as compared to the women with severe preeclampsia (p < 0.0001). In women with preeclampsia, the mean umbilical blood homocysteine level was by 0.268 µmol/L lower than the respective level measured in control group (p < 0.0001). In women with preeclampsia, the mean homocysteine level was by 0.878 µmol/L lower in the same group of women six months after delivery (p < 0.0001).

**Conclusion:** Homocysteine are lower in preeclamptic women six months after delivery. The neonates born to mothers with preeclampsia are not at a higher exposure to homocysteine.

**INTRODUCTION**

Since the 1990s, homocysteine has been associated with disorders of the fetomaternal unit (1). Studies on recurrent abortions also found clear association between elevated homocysteine levels and the risk of abortion (2,3). Later on, Vollset et al. (4) found the levels of homocysteine to be associated with the prevalence of preeclampsia, preterm delivery, low birth, intrauterine growth restriction (IUGR), stillbirth, congenital malformations and abruptio placentae. The association of mild hyperhomocysteinemia with cardiovascular disease and related mortality was demonstrated in a number of studies (5-11).

Hyperhomocysteinemia alters vascular morphology, stimulates inflammation, activates endothelium and blood clotting cascade, and inhibits fibrinolysis. Hyperhomocysteinemia results in the loss of endothelial antithrombin function and induction of a procoagulant setting (9,12). The pathogenetic action of homocysteine also includes interference with the nitric oxide (NO) system (homocysteine reduces NO bioavailability by interfering with its synthesis), activation of transcript-
tion factors stimulating gene expression (activation of sterol-regulatory element-binding protein (SREBP) and protein kinase C (PKC), lipid biosynthesis), chemotaxis and leukocyte adhesion (ICAM-1, VCAM-1, interleukin-8, von Willebrand’s factor) (13,14).

The aims of the study were to assess the association between elevated homocysteine levels and development of preeclampsia; to determine homocysteine levels in fetal circulation; to differentiate homocysteine levels in mild and severe preeclampsia; and to compare homocysteine levels in pregnant women with preeclampsia with homocysteine levels measured in the same group of women six months after delivery.

**METHODS**

The study included 55 pregnant women with verified mild preeclampsia (blood pressure measured on two occasions at least 4 hours apart ≥140/90 mm Hg after 20th week of gestation, and positive proteinuria) and severe preeclampsia (blood pressure ≥160/110 mm Hg, proteinuria ≥+++). Control group consisted of 50 healthy pregnant women, as approved by the Ethics Committee of the Osijek University Hospital. All pregnant women are taking folate supplements and vitamins, including B6 and B12 during pregnancy and puerperium (Elevit®, Bayer, Germany). In both preeclampsia and control group, homocysteine levels were measured after at least 12-hour fasting. Umbilical blood homocysteine levels were determined in the same groups of women after delivery, during third stage. In the group of women with preeclampsia, blood homocysteine was also determined six months after delivery. Homocysteine levels were determined by the FPIA (fluorescence polarization immunoassay) technology on an AxSYM device (Abbott Laboratories) using reagents of the same manufacturer (Testkit Code No. 5F51-20). According to Khong and Hague (15), hyperhomocysteinemia is present in pregnant women when the level of homocysteine exceeds 10.9 μmol/L.

On statistical analysis, the basic characteristics of the sample consisting of women with preeclampsia and control women were determined first. Because of the relatively small number of study subjects, the Shapiro-Wilks test, t-test for dependent variables and Levene’s test were used. When the Shapiro-Wilks test failed to confirm the hypothesis of normal distribution, Mann-Whitney and Wilcoxon tests were employed. Differences confirmed at the level of p<0.05 were considered to be statistically significant. Data were prepared by use of the Microsoft Excel calculator, while the SPSS and Statistica packages were used on data processing. Box and Whisker Plot diagrams were done by the Statistica application because the reasons stated statistical data processing.

**RESULTS**

Age and parity in two groups were no statistic significantly, but gestational age in preeclamptic women are shortly 35.5 vs 39.1 weeks (p<0.0001) because high number induced and preterm delivery.

In women with preeclampsia, the mean homocysteine level was 6.758 μmol/L. According to median, the mean level of homocysteine was ≤6.4 μmol/L and ≥6.4 μmol/L in 50% of women with preeclampsia each. In control group, the mean homocysteine level was 6.014 μmol/L. According to median, the mean homocysteine level was ≤5.8 μmol/L and ≥5.8 μmol/L in 50% of control women each. The lowest and highest homocysteine level was 2.6 μmol/L and 9.8 μmol/L, respectively, yielding a range of variation of 7.2 μmol/L (Figure 1). In preeclampsia group, the mean homocysteine level was greater by 0.744 μmol/L and the median calculated for these women by 0.6 μmol/L than the respective values recorded in control group. The Mann-Whitney test indicated nonexistence of statistically significant differences in homocysteine levels between the group of women with preeclampsia and control group (Z=-1.733, p=0.083). In women with mild preeclampsia, the mean homocysteine level was 6.008 μmol/L. The lowest and highest homocysteine level was 3.9 μmol/L and 8.6 μmol/L, respectively, yielding a range of variation of 4.7 μmol/L. In women with severe preeclampsia, the mean homocysteine level was 8.760 μmol/L. According to median, the mean homocysteine level was ≤8.6 μmol/L and ≥8.6 μmol/L in 50% of women with severe preeclampsia each. In women with mild preeclampsia, the mean homocysteine level was by 2.752 μmol/L lower than the mean homocysteine level recorded in women with severe preeclampsia, whereas the median

![Figure 1. Box and Whisker Plot diagram of variables defined as homocysteine level in women with preeclampsia and control women.](image-url)
Homocysteine are lower in preeclamptic women six months after delivery

M. Vuković Bobić et al.

Figure 2. Box and Whisker Plot diagram of variables defined as homocysteine level in women with mild preeclampsia and severe preeclampsia.

Figure 3. Box and Whisker Plot diagram of variables defined as umbilical homocysteine level in women with preeclampsia and control women.

Figure 4. Box and Whisker Plot diagram of variables defined as homocysteine level in women with preeclampsia before and after delivery.

between pregnant women with mild preeclampsia and those with severe preeclampsia ($Z = -4.199, p < 0.0001$).

In the neonates born to mothers with preeclampsia and those born to mothers from control group, the mean level of umbilical homocysteine was 5.044 μmol/L and 5.312 μmol/L, respectively (Figure 3). In women with preeclampsia, the mean homocysteine level was by 0.268 μmol/L lower than the respective level measured in control women, while the median calculated for women with preeclampsia was lower by 0.2 μmol/L. Spearman's rank correlation coefficient between maternal and umbilical homocysteine yielded a moderately positive statistically significant correlation ($\rho = 0.670, p < 0.0001$). In women with preeclampsia, the mean homocysteine level was 6.758 μmol/L. According to median, the mean homocysteine level was ≤6.4 μmol/L and ≥6.4 μmol/L in 50% of women with preeclampsia each. The mean homocysteine level measured in women with preeclampsia six months after delivery was 7.636 μmol/L (Figure 4). In pregnant women with preeclampsia, the mean homocysteine level was lower by 0.878 μmol/L and the median calculated for these women by 1.3 μmol/L than the respective figures recorded six months after delivery. Wilcoxon test yielded a statistically significant difference in homocysteine level in preeclampsia women before and after delivery ($Z = -3.604, p < 0.0001$).

DISCUSSION

The pattern of the amino acid homocysteine behavior in preeclampsia has been investigated in many studies,
with sharply opposed results. In the study by Powers et al. (16), the mean homocysteine levels were significantly elevated (p<0.04) in women with preeclampsia as compared with control group (9.7 μmol/L vs. 7.0 μmol/L). Similar results (6.7 μmol/L vs. 3.8 μmol/L; p<0.01) have also been reported by Laviouri et al. (17). These two studies were of a similar design, conducted in a sample of 50 primiparae; however, in the former study, blood samples were obtained before delivery after 6-hour fasting, whereas in the latter blood samples were collected during third trimester after at least 12-hour fasting. Therefore, differences in the mean homocysteine levels could be ascribed to variation in sampling time. Rajkovic et al. (18) conducted a study on African women and found the risk of developing preeclampsia to be 4.57-fold greater (OR=4.57; 95%CI: 2.11-9.88) in women with higher homocysteine levels, whereas Sorensen et al. (19) demonstrated the respective risk to be 3.2-fold greater (OR=3.2; 95%CI: 1.11-9.2). The latter two studies showed the risk to increase significantly in primiparae in comparison with multiparae with comparable homocysteine levels. The risk was 12.9-fold greater in African primiparae (OR=12.9; 95%CI: 5.28-31.53) and 9.7-fold greater in American primiparae (OR=9.7; 95%CI: 2.14-14). Both studies were adjusted for various confounding factors by multivariate analysis. Variations between the studies could be attributed to differences in the number of study subjects (more than double in the former study) and the time of blood sampling because it was performed after delivery in African women and in second trimester in American women. Our results showed the mean homocysteine level (6.758±2.062 μmol/L) and median (6.400 μmol/L) calculated for women with preeclampsia to exceed the respective values recorded in the control group of women free from preeclampsia (6.014±1.539 μmol/L and 5.800 μmol/L); however, the between-group difference in homocysteine levels did not reach statistical significance. Makedos et al. (20) compared homocysteine levels in a group of pregnant women with preeclampsia and control group free from preeclampsia and found the mean homocysteine level to be significantly increased in the former (11.11 μmol/L vs. 6.40 μmol/L; p<0.001). There was no between-group difference in the folic acid and vitamin B12 levels. The group of women with preeclampsia was associated with a higher rate of cesarean section, IUGR (50%) and abruptio placentae (20).

Malinow et al. (21) investigated the relationship of homocysteine levels in maternal venous blood, umbilical vein and umbilical artery and found a decreasing concentration gradient with 1 μmol/L difference for each of the samples tested. The mean homocysteine level in maternal plasma was 5.43±1.40 μmol/L, by approximately 1 μmol/L greater than the mean homocysteine level in umbilical vein (4.94±1.78 μmol/L). These authors also report on positive correlation between umbilical homocysteine (umbilical artery and umbilical vein) and maternal plasma homocysteine. Based on these results, they suggest the possibility of transplacental transfer of maternal homocysteine to the umbilical vein, thus being incorporated in the fetal metabolic cycle. These authors also found negative correlation of maternal homocysteine with gestational age and neonatal birth weight, and explain it by fetal utilization of homocysteine proportionate to fetal weight and gestational age (21). These results explain the homocysteine decline in normal pregnancy (21,22). Similar results were also recorded in the present study; however, in the group of pregnant women with preeclampsia, the mean homocysteine level was lower than the respective level measured in the same group of women six months after delivery, the difference being statistically significant.

In contrast to the studies mentioned above but similar to our results, Mignini et al. (23) published results of a systematic review that included 25 studies, 8 and 17 of which measured serum homocysteine levels before and after the onset of preeclampsia, respectively. In many of these studies, differences in the mean homocysteine levels according to gestational age were recorded both in normal pregnancy and in women with preeclampsia, especially those with severe preeclampsia (mean difference: 1.42 μmol/L, 95%CI: 0.53-2.30), unlike women with mild preeclampsia (mean difference: 0.60 μmol/L, 95%CI: 0.30-0.89). These biological gradients were not statistically significant.

The investigators analyzed the possible etiologic factors of hyperhomocysteinemia (folate and vitamin B12 levels and genetic polymorphisms) and found no association with hyperhomocysteinemia. Then they assessed the possible effect of hyperhomocysteinemia on the development of preeclampsia via oxidative stress and endothelial dysfunction, as we also postulated in our study, and found the studies reviewed to report divergent input and poor correlation of the factors assessed, i.e. absence of biological plausibility; therefore, they consider that the association of hyperhomocysteinemia and preeclampsia cannot be explained by the current literature data (23). In contrast to the study by Mignini et al. (23), a more recent report by Acilmis et al. (24) offers an explanation of the obscurities related to hyperhomocysteinemia and pregnancy by differentiating severe and mild preeclampsia. They monitored the levels of homocysteine, folic acid and vitamin B12 in three groups of pregnant women, i.e. severe preeclampsia, mild preeclampsia and normal pregnancy, and found statistically significantly higher homocysteine levels in maternal and fetal (umbilical) blood in the group of women with severe preeclampsia as compared with the groups of women with normal pregnancy and those with mild preeclampsia. There was no statistically significant difference in the levels of maternal and fetal (umbilical) homocysteine between the groups of women with normal pregnancy and those with mild preeclampsia. There was no statistically significant between-group difference in folic acid and vitamin B12 levels in
maternal and fetal (umbilical) samples either. The authors conclude that the levels of homocysteine are significantly higher in the group of women with severe preeclampsia as compared with the groups of women with mild preeclampsia and those with normal pregnancy, suggesting that the increased homocysteine levels may be associated with the severity of preeclampsia. They also consider that elevated homocysteine levels do not appear to be accompanied by folic acid and vitamin B12 deficiency (24). A similar homocysteine pattern was also observed in our study. Subdivision of our group of pregnant women according to the severity of preeclampsia based on the criteria of blood pressure ≥160/110 mm Hg and proteinuria ≥++ (10 mg/dL) yielded two subgroups of women (15 with severe preeclampsia and 40 with mild preeclampsia) that differed significantly according to the mean homocysteine levels. In the subgroup of women with severe preeclampsia, the mean homocysteine level (8.760±2.156 μmol/L) and median (8.6 μmol/L) exceeded the respective values recorded in women with mild preeclampsia (6.008±1.449 μmol/L and 5.8 μmol/L, respectively). White et al. proven of differences in homocysteine levels between the subgroups were also statistically significant. A history of hypertension in pregnancy, when compared with normotensive pregnancy, was associated with a 4.5% higher serum homocysteine level and 1.60-fold increased odds of having an elevated after adjusting for potentially confounding covariates. A history of normotensive pregnancy, as compared with nulliparity, was associated with a 6.1% lower serum homocysteine level and a 0.49-fold reduced odds of elevated homocysteine levels (25). Other recently investigations they found significantly higher values umbilical homocysteine in womens with severe preeclampsia, but without only indicate some degree of in-utero fetal cardiac cell damage (26).

Our results suggested that there was no difference in homocysteine levels between normal pregnancies and pregnancies complicated by preeclampsia, but homocysteine levels in women with preeclampsia were statistically significantly lower than homocysteine levels measured in the same group of women six months after delivery. In women with severe preeclampsia, homocysteine levels exceeded those in women with mild preeclampsia. However, our study results yielded no statistical evidence for the infants born to mothers with preeclampsia to be at a higher exposure to homocysteine than those born to mothers with normal pregnancy.

REFERENCES


